Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Apr 12 2024;13(4)doi:10.3390/antiox13040455
CagriSema, the combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, produced an estimated mean body weight reduction of 20.4% compared to 3.0% with placebo
FDA approval, if granted, would likely occur in late 2026 or early 2027 based on typical review timelines
However, using an on-treatment exposure definition that followed patients while they were continuously exposed to the study drugs likely mitigated this bias
US$ 20.12
US$ 21.95
US$ 26.04
US$ 28.48
